ClinicalTrials.gg
CompletedNCT06773767Updated Sep 3, 2025

Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state.

A Phase 1 interventional study of 150 mg trazodone hydrochloride and 300 mg trazodone hydrochloride in Bioavailability Heathy Volunteers, Bioavailability Study and Bioequivalance, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled May 2024, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Two way, two parallel groups, crossover study to compare the bioavailability of 150 mg and 300 mg trazodone hydrochloride (new polymer) (Angelini Pharma S.p.A.) vs. 150 mg and 300 mg trazodone hydrochloride Contramid® (Angelini Pharma S.p.A.) at steady-state in 64 Healthy Volunteers.

02

Conditions studied

  • Bioavailability Heathy Volunteers
  • Bioavailability Study
  • Bioequivalance

Keywords

  • Bioavailability
  • Oral multiple dose
  • Bioequivalence
03

In context

Lead sponsor

Aziende Chimiche Riunite Angelini Francesco S.p.A is the lead sponsor of 40 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sex: male/female
  • Age: 18 to 65 years inclusive
  • Body-mass index (): ≥ 18.5 kg/m² and ≤ 30.0 kg/m²
  • Good state of health
  • Non-smoker or ex-smoker for at least 3 months
  • Written (including consent on personal data processing), after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial

Exclusion criteria

Exclusion Criteria:

  • Existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient.
  • Existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient.
  • Existing gastrointestinal diseases or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient.
  • Presence or history of relevant and currently treated CNS and/or psychiatric disorders.
  • History of suicidal behaviour, suicidal intentions and/or suicidality among family members.
  • Nurses Global Assessment of Suicide Risk (NGASR)-scale showing a high or very high risk.
  • Known allergic reactions or to the active ingredient used or to constituents of the pharmaceutical preparations
  • History of severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the Investigator
  • History of alcohol intoxication
  • History or known hyperthyroidism regardless of adequate treatment
  • History of or known micturition disorders
  • History of or known current increased intraocular pressure
  • Known hypotension, orthostatic syndrome or repeated occurrence of syncope
  • History of or current priapism
  • History of intoxication with drugs that attenuate the CNS or antihypertensives
  • Current treatment with opioids or serotonergic agents.
  • Systolic blood pressure \< 90 or > 139 mmHg and diastolic blood pressure \< 60 or > 89 mmHg Heart rate \< 50 bpm or > 90 bpm
  • > 450 ms for men and > 470 ms for women
  • Laboratory values out of normal range unless the deviation from normal is judged as not relevant for the clinical trial by the Investigator.
  • ASAT > 20 % , ALAT > 10 % ULN, > 20% ULN and creatinine > 0.1 mg/dL ULN.
  • Positive anti--test, HBs-antigen-test, or anti--test
  • Vaccination against COVID-19 within the last 4 weeks prior to individual intended IMP administration
  • Acute or chronic diseases which may interfere with the pharmacokinetics of the IMP
  • History of or current drug or alcohol dependence
  • Positive alcohol or drug test at screening examination
  • Regular intake of alcoholic food or beverages of ≥ 24 g pure ethanol for male or ≥ 12 g pure ethanol for female per day
  • Subjects who are on a diet which could affect the pharmacokinetics of the active ingredient
  • Regular intake of caffeine containing food or beverages of ≥ 500 mg caffeine per day
  • Blood donation or other blood loss of more than 400 ml within the last 6 months prior to individual enrolment of the subject
  • Participation in a clinical trial with administration of any medicinal product during the last 6 months prior to individual enrolment of the subject
  • Simultaneous participation in another clinical trial with active ingredients
  • Regular treatment with any systemically available medication
  • Subjects, who report a frequent occurrence of migraine attacks
  • Positive pregnancy test at screening examination
  • Pregnant or lactating women
  • Female subjects who do not agree to apply highly effective methods
  • Subject is vulnerable such as detained or committed to an institution by a court of law or by legal authorities or has a close affiliation with the Sponsor or the investigational site; e.g., a close relative of the investigator, dependent person, employee of the Sponsor or affiliates
  • Subjects suspected or known not to follow instructions
  • Subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Group 1: 150 mg

    Treatment with two differet formulations of 150 mg trazodone hydrochloride during treatment period

    Drug: 150 mg trazodone hydrochloride

  • Experimental
    Group 2: 300 mg

    Treatment with two different formulations of 300 mg trazodone hydrochloride during treatment period

    Drug: 300 mg trazodone hydrochloride

Interventions

  • To compare the bioavailability of 150 mg trazodone hydrochloride tablets (new polymer) vs. 150 mg trazodone hydrochloride Contramid® tablets at steady-state.

  • To compare the bioavailability of 300 mg trazodone hydrochloride tablets (new polymer) vs. 300 mg trazodone hydrochloride Contramid® tablets at steady-state

06

What researchers measure

Primary outcomes

  1. Assessment of bioequivalence of two different formulations of trazodone hydrochloride tablets 150 mg

    Assessment of bioequivalence of Test 1 in comparison to Reference 1 after multiple dose administration under fasting conditions determined by means of the AUC(0-Tau),ss, of trazodone.

    Time frame: 5 days

  2. Assessment of bioequivalence of two different formulations of trazodone hydrochloride tablets 150 mg

    Assessment of bioequivalence of Test 1 in comparison to Reference 1 after multiple dose administration under fasting conditions determined by means of the CTau, ss of trazodone.

    Time frame: 5 days

  3. Assessment of bioequivalence of two different formulations of trazodone hydrochloride tablets 150 mg

    Assessment of bioequivalence of Test 1 in comparison to Reference 1 after multiple dose administration under fasting conditions determined by means of the Cmax,ss of trazodone.

    Time frame: 5 days

  4. Assessment of bioequivalence of two different formulations of trazodone hydrochloride tablets 300 mg

    Assessment of bioequivalence of Test 2 in comparison to Reference 2 after multiple dose administration under fasting conditions determined by means of the AUC(0-Tau),ss of trazodone

    Time frame: 5 days

  5. Assessment of bioequivalence of two different formulations of trazodone hydrochloride tablets 300 mg

    Assessment of bioequivalence of Test 2 in comparison to Reference 2 after multiple dose administration under fasting conditions determined by means of the CTau,ss of trazodone

    Time frame: 5 days

  6. Assessment of bioequivalence of two different formulations of trazodone hydrochloride tablets 300 mg

    Assessment of bioequivalence of Test 2 in comparison to Reference 2 after multiple dose administration under fasting conditions determined by means of the Cmax,ss of trazodone

    Time frame: 5 days

Secondary outcomes

  1. Comparison of pharmacokinetic profiles (Concentration) of Test and Reference products

    Concentration at the end of the dosing interval after the 1st, 2nd, 3rd and 4th IMP administration during treatment phase, considering scheduled times

    Time frame: 5 days

  2. Comparison of pharmacokinetic profiles (Cmin, ss) of Test and Reference products

    Observed (absolute) minimum concentrations within the dosing interval Tau (profile day), considering scheduled times

    Time frame: 5 days

  3. Comparison of pharmacokinetic profiles (Fluctuation%) of Test and Reference products

    Fluctuation as peak trough fluctuation, fluctuation% = {\[Cmax,ss - Cmin,ss\]/Cav} •100%

    Time frame: 5 days

  4. Comparison of pharmacokinetic profiles (Cav)of Test and Reference products

    Average concentration at steady-state, Cav = AUC(0-Tau),ss/Tau

    Time frame: 5 days

  5. Comparison of pharmacokinetic profiles (Tmax, ss))of Test and Reference products

    Time to reach the maximum concentration within each dosing interval (profile day), obtained directly from the data

    Time frame: 5 days

  6. Descriptive characterisation of safety of Test and Reference products

    Descriptive characterisation of safety of Test and Reference products considering adverse events observed during the trial

    Time frame: 8 days

  7. Descriptive characterisation of tolerability of Test and Reference products

    Descriptive characterisation of tolerability of Test and Reference products considering adverse events observed during the trial

    Time frame: 8 days

07

Study locations

1 site
  • SocraTec R&D GmbH Clinical Pharmacology
    Erfurt, Germany 99084, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Aug 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2024
First posted
Jan 14, 2025
StartActual
May 22, 2024
Primary completionActual
Aug 7, 2024
CompletionActual
Aug 7, 2024
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06773767
Collaborators
SocraTec R&D GmbH
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
May 22, 2024
Primary completion
Aug 7, 2024
Completion
Aug 7, 2024
Last update
Sep 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion